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Ceiling effects in the 
“Effectiveness of adjunctive 
antidepressant treatment for 
bipolar depression” study: 
was the sky the limit?
Efeitos do teto no estudo 
“Eficácia do tratamento 
antidepressivo adjuvante para 
depressão bipolar”: era o céu 
o limite?
The widely discussed study by Sachs et al., namely the 
Effectiveness of adjunctive antidepressant treatment for bipolar 
depression is based on a pragmatic trial that randomly assigned 
bipolar depression patients to receive mood stabilizer plus placebo 
or mood stabilizer plus antidepressant. It achieved similar results 
in terms of durable recovery and other secondary outcomes. 
Considering that the aforementioned study employed a new 
methodological approach, I believe that it would be worthwhile 
exploring its advantages and disadvantages so as to be better 
positioned to interpret current studies, as well as to design new 
ones. Based on the aspects listed below, I would like to discuss 
whether or not the study contains a “ceiling effect” i.e., a false 
negative finding resulting from performance and selection biases.
1) Refractoriness – In the study by Sachs et al., 60% of the 
patients presented more than 10 previous manic and depressive 
episodes,1 thus suggesting that this group may constitute a 
refractory sample. Refractoriness is associated with poor treatment 
outcomes and, therefore, to ceiling effects.2 For instance, in 
the Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D) study, the cumulative remission rates after one, two, 
three or four antidepressant trials were 33%, 57%, 63% and 67%, 
respectively.3 Sachs et al. aimed at detecting an absolute difference 
of 15% between groups, a goal that could hardly be achieved had 
the subjects presented at least a moderate rate of refractoriness.
2) Strict primary outcomes – the primary outcome of the Sachs 
et al. study was “durable recovery”, defined as eight consecutive 
weeks of euthymia, with no more than two manic or depression 
symptoms. This is a more orthodox criterion when compared to 
the criterion generally applied to most antidepressant trials, which 
tend to define remission as a mood score <10 points, which, in 
turn, can be translated as the presence of 4 to 5 mild or 2 to 3 
moderate symptoms.4 When stricter outcome criteria are adopted, 
both the experimental and the control interventions are more likely 
to yield similar response rates, thus leading to a ceiling effect. 
3) Excessive “noise” - clinical trials are ultimately designed to 
detect whether treatment effects (the “signal”) surpass non-specific 
effects (the “noise”). In the Sachs et al. study, patients were allowed 
to increase the dose of the mood stabilizer and enhance the use 
of pharmacotherapy, psychotherapy, etc. Such factors could have 
increased the trial “noise” by increasing non-specific effects at the 
expense of decreasing the “signal” of the experimental treatment. 
4) Design issues – Sachs et al. compared mood stabilizer + 
placebo against mood stabilizer + antidepressant drug. In such 
type of design, ceiling effects are important since the effect of 
the combined intervention is weaker compared to the effect 
of each intervention tested separately.2 For example, when two 
treatments whose individual remission rate is set at 50% are 
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combined, the combined treatment is not likely to lead to full 
remission (100%). To assess an antidepressant’s efficacy, which was 
probably lower in the Sachs et al. study, the study’s design should 
have included a pure placebo arm. The study, however, followed 
the ethical principle of equipoise, which states that should be 
genuine uncertainty on the preferred treatment when designing 
interventional studies.5 Therefore, the use of pure placebo arms in 
pragmatic, phase IV studies is unfeasible due to ethical concerns 
involving the offering of an inferior treatment for a prolonged 
period of observation.
In conclusion, given that the number of pragmatic trials in 
Psychiatry has increased over time, we are now allowed to test the 
effectiveness of interventions in the “real world”. As exemplified 
by the Sachs et al. study, such trials, however, have certain design 
characteristics that can lead to ceiling effects. Therefore, when 
translating results into clinical practice, clinicians should be aware 
of the possible caveats to be found in pragmatic studies. 
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Suicídio em adolescentes no 
Brasil: problema de saúde 
publica?
Suicide among adolescents in 
Brazil: public health problem?
Caro Editor, 
Em artigo recém publicado, “Ideação suicida em adolescentes 
de 11 a 15 anos: prevalência e fatores associados”, Souza et al. 
abordaram um assunto muito importante sobre a prevalência 
(14,1%) e fatores associados à ideação suicida entre adolescentes, 
tais como ser do gênero feminino (principalmente as jovens com 
vida sexual ativa), sofrer de provável problema mental e uso de 
substâncias psicoativas1. Esta publicação nos leva a considerar 
algumas questões de saúde pública.
A primeira questão refere-se à necessidade de conhecimento 
atualizado e sistematizado sobre a frequência de ideação suicida, 
a frequência das tentativas de suicídio e, por fim, o número de 
suicídios completos. A cidade de São Paulo tem 1.628.589 jovens 
entre 10 e 19 anos, sugerindo uma prevalência de 2/100.000 casos 
de suicídio nessa população, com maior concentração de suicídio 
completo entre 15 e 19 anos e com métodos mais violentos (Tabela 
1). Porém, não dispomos de dados sobre as tentativas de suicídio, 
o que seria necessário para delinearmos um cenário mais preciso 
acerca do risco dessa população e assim estabelecer os planos de 
ação visando à prevenção. 
O segundo aspecto é o reduzido número de pesquisas sobre 
o desenvolvimento dos transtornos mentais desde a infância e 
a busca de uma nova metodologia para identificar transtornos 
mentais e sintomas precoces na população infantil2. Nesse sentido, 
seria fundamental que a Psiquiatria buscasse critérios para a 
definição de casos “com risco”, desenvolvendo metodologias que 
identificassem estes indivíduos e realizassem intervenções antes 
